Downloads and Tools

•  Article PDF
  687.17 KB PDF document

This is an open access article.
Print this page Email this page

Recipient's Email:

---

Article Citation

RIS
MARC (XML)
FULL CITATION (TXT)

---

Share on Facebook

Authors: Kristina A. Bryant, Jodie McVernon, Colin D. Marchant, Terry Nolan, Gary S. Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen B. Lambert, Emmanuel Aris, Narcisa Mesaros and Jacqueline M. Miller

Kristina A. Bryant

Corresponding author: k0brya01@louisville.edu
University of Louisville; Louisville, KT USA

Jodie McVernon

Vaccine & Immunisation Research Group, Murdoch Children's Research Institute and University of Melbourne; Melbourne, VIC Australia

Colin D. Marchant

Boston University Medical Center; Boston, MA USA

Terry Nolan

Vaccine & Immunisation Research Group, Murdoch Children's Research Institute and University of Melbourne; Melbourne, VIC Australia

Gary S. Marshall

University of Louisville; Louisville, KT USA

Peter Richmond

University of Western Australia School of Paediatrics and Child Health, Telethon Institute for Child Health Research, and Princess Margaret Hospital for Children; Perth, Australia

Helen Marshall

School of Paediatrics and Reproductive Health; University of Adelaide, Adelaide; SA Australia; Vaccinology and Immunology Research Trials Unit; Women’s and Children’s Hospital; North Adelaide, SA Australia

Michael Nissen

Queensland Paediatric Infectious Diseases Laboratory; Queensland Children’s Medical Research Institute; Royal Children’s Hospital and The University of Queensland; Brisbane, QLD Australia

Stephen B. Lambert

Queensland Paediatric Infectious Diseases Laboratory; Queensland Children’s Medical Research Institute; Royal Children’s Hospital and The University of Queensland; Brisbane, QLD Australia

Emmanuel Aris

GlaxoSmithKline Biologicals; Wavre, Belgium

Narcisa Mesaros

GlaxoSmithKline Biologicals; Wavre, Belgium

Jacqueline M. Miller

GlaxoSmithKline Biologicals; King of Prussia, PA USA

Abstract:
A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjugated to N. meningitidis outer membrane protein) coadministered with measles-mumps-rubella (MMR) and varicella (VAR) vaccines (NCT00134719/NCT00289783). Noninferiority of immunological responses to MMR and VAR was demonstrated between groups and incidences of MMR- and VAR-specific solicited symptoms were similar, indicating that HibMenCY-TT can be coadministered with MMR and VAR.

Received: November 30, 2011; Accepted: April 12, 2012; Published Online: August 1, 2012

Preview: